Orano joins the Working with Cancer campaign
While cancer is an undeniable reality in our personal and professional environment, the group has been keen to engage in support initiatives at work to improve screening of its employees, encourage the adoption of behaviors favorable to health, and improve support for personnel with a potential cancer diagnosis.
A Working with Cancer pledge to give formal expression to a commitment to health
The decision to join the campaign launched by CEO of Publicis Groupe, Arthur Sadoun, is aligned with the Orano group’s commitment to deploying support and prevention initiatives for all employees in the 17 countries where it operates. This undertaking, embodied by the Working with Cancer pledge, complements agreements signed by Orano’s Executive Management team and representative trade union organizations which for years have illustrated the company’s proactive policy in championing diversity, inclusion, gender equality and the professional development of each employee.
Three priorities for employees worldwide
One in two people will be affected by cancer during their lifetime. Given the differences in care and treatment between countries, it was important for the group to make a formal commitment that could be applied worldwide. This signature also aims to break down the wall of silence and start a conversation with employees who are suffering with cancer: while 50% of cancer sufferers are afraid to talk about it with their employer, 92% of patients believe that support in the workplace has a positive impact on their health.
Under the Working with Cancer pledge, Orano undertakes to:
- Inform and raise awareness around active listening among managers, group health teams and all our employees worldwide
- Promote cancer screening and
prevention
- Support employees affected by cancer in staying in work or returning to work
Taking part in the fight against cancer, a longstanding commitment
For fifteen years now, the group has been involved in the fight against cancer with Orano Med. The ambition of the group's subsidiary is to develop a new generation of targeted cancer therapies, thanks to the unique properties of lead-212. This year, Orano Med and Sanofi have pooled their expertise to accelerate the development of innovative treatments for patients with unmet needs.